This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Insomnia; diabetes; cardiovascular disease	Casein kinase 1δ (CSNK1D; CKI-δ)	A small molecule inhibitor of CKI-δ that prolongs circadian rhythms could help guide drug development for diseases driven by circadian disruption. Disruption of the circadian rhythm has been linked to sleep disorders, diabetes and cardiovascular disease. In cell culture, the small molecule benzothiazole derivative LH846 reduced phosphorylation of the transcription factor period homolog 1 (PER1) and prolonged the circadian cycle of cells compared with vehicle control. Next steps could include studying LH846 in animal models of diseases driven by circadian disruption.	Patent and licensing status unavailable	Lee, J.W. <i>et al. Angew. Chem. Int. Ed.</i> ; published online Sept. 26, 2011; doi:10.1002/anie.201103915 Contact: Steve A. Kay, University of California, San Diego, La Jolla, Calif. e-mail: skay@ucsd.edu Contact: Peter G. Schultz, The Scripps Research Institute, La Jolla, Calif. e-mail: schultz@scripps.edu
<i>SciBX</i> 4(41); doi:10.1038/scibx.2011.1156 Published online Oct. 20, 2011				